Literature DB >> 10147231

An evaluation of antihypertensive prescribing practices.

D A Knapp1, R J Michocki, J P Richardson, D A Knapp1.   

Abstract

We evaluated the management of patients with hypertension (including drug prescribing) by US physicians, compared their prescribing to National Institutes of Health (NIH) guidelines, and compared the pharmacoeconomics of the prescribed antihypertensive drugs. A 1991 national US database, using physician-patient encounter forms, was our data source. Results showed that physicians generally met the NIH guidelines regarding diagnostic/screening services, patient counselling/education, antihypertensive drug prescribing and follow-up. Two areas should be the foci of continuing medical education for US physicians. Firstly, physicians need to be reminded that centrally acting alpha 2-agonists are optimally used as supplemental antihypertensive drugs rather than as initial agents, which is how some physicians utilised them. Secondly, if once-daily administration is used to promote patient compliance, physicians should be aware that, of the frequently prescribed first-line antihypertensive drugs, hydrochlorothiazide, chlorthalidone and atenolol presently have substantially less expensive once-daily dosage forms than other diuretics or beta-blockers, calcium antagonists or ACE inhibitors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 10147231     DOI: 10.2165/00019053-199405050-00007

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  1 in total

1.  Variability in antihypertensive drug therapy in general practice: results from a random national survey.

Authors:  I Kawachi; L A Malcolm; G Purdie
Journal:  N Z Med J       Date:  1989-06-28
  1 in total
  1 in total

1.  Dynamic competition as an exploratory model of healthcare policy for the antihypertensive market.

Authors:  R J Bonk; M J Myers; C H Knowlton; D Sabapathi; W F McGhan
Journal:  Pharmacoeconomics       Date:  1996-09       Impact factor: 4.981

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.